Enterprise Value

4.038B

Cash

330M

Avg Qtr Burn

-42.44M

Short % of Float

11.65%

Insider Ownership

57.47%

Institutional Own.

45.41%

Qtr Updated

06/30/23


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & IndicationStage & EventCatalyst Date

Phase 3

Data readout

Phase 3

Data readout

Batoclimab (IMVT-1401) Details
Chronic inflammatory disorder

Phase 2b

Data readout

Phase 2

Data readout

IMVT-1402 Details
Autoimmune disease, Warm autoimmune hemolytic anemia

Phase 1

Update

Batoclimab (IMVT-1401) Details
Warm autoimmune hemolytic anemia

Failed

Discontinued